Brokerages Expect Tetraphase Pharmaceuticals Inc (TTPH) Will Announce Quarterly Sales of $2.18 Million
Wall Street analysts expect Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) to announce $2.18 million in sales for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Tetraphase Pharmaceuticals’ earnings, with the highest sales estimate coming in at $3.60 million and the lowest estimate coming in at $750,000.00. Tetraphase Pharmaceuticals posted sales of $11.58 million during the same quarter last year, which suggests a negative year-over-year growth rate of 81.2%. The company is scheduled to report its next earnings results on Thursday, August 1st.
According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full-year sales of $10.05 million for the current financial year, with estimates ranging from $4.10 million to $16.57 million. For the next fiscal year, analysts forecast that the business will report sales of $24.40 million, with estimates ranging from $10.50 million to $49.37 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover Tetraphase Pharmaceuticals.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. Tetraphase Pharmaceuticals had a negative net margin of 383.19% and a negative return on equity of 80.01%. The firm had revenue of $1.27 million during the quarter, compared to analyst estimates of $1.93 million.
TTPH opened at $0.88 on Thursday. The company has a debt-to-equity ratio of 0.53, a current ratio of 7.28 and a quick ratio of 7.10. Tetraphase Pharmaceuticals has a 52 week low of $0.86 and a 52 week high of $4.49. The firm has a market cap of $47.70 million, a price-to-earnings ratio of -0.64 and a beta of 2.85.
Several hedge funds and other institutional investors have recently made changes to their positions in TTPH. Paloma Partners Management Co bought a new position in shares of Tetraphase Pharmaceuticals during the fourth quarter worth $33,000. Gamco Investors INC. ET AL boosted its position in shares of Tetraphase Pharmaceuticals by 42.9% during the fourth quarter. Gamco Investors INC. ET AL now owns 50,000 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 15,000 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Tetraphase Pharmaceuticals during the fourth quarter worth $69,000. Rhumbline Advisers boosted its position in shares of Tetraphase Pharmaceuticals by 40.6% during the fourth quarter. Rhumbline Advisers now owns 72,976 shares of the biopharmaceutical company’s stock worth $82,000 after purchasing an additional 21,089 shares in the last quarter. Finally, State of Wisconsin Investment Board boosted its position in shares of Tetraphase Pharmaceuticals by 29.8% during the first quarter. State of Wisconsin Investment Board now owns 71,000 shares of the biopharmaceutical company’s stock worth $95,000 after purchasing an additional 16,300 shares in the last quarter. 42.23% of the stock is currently owned by institutional investors.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Featured Story: Commodities
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.